Serpin A-6 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Corticosteroid-binding globulin (SERPINA6 / CBG; UniProt P08185) produced in HEK293 cells. Suitable for binding assays, ELISA quantification standards, proteomic reference material, and antibody validation paired with RP-SerpinA6.
Expression system
HEK293
Cat. #
REC-SerpinA6

In stock

SKU
REC-SerpinA6
$498.00

Target Overview

Serpin A-6 — formally Corticosteroid-binding globulin (CBG), also known as Transcortin — is a secreted glycoprotein and the principal plasma carrier for glucocorticoids and progestins across virtually all vertebrate species. Encoded by SERPINA6 and catalogued under UniProt P08185, the mature human protein spans 405 amino acid residues and belongs to the serine protease inhibitor (serpin) superfamily, though it functions primarily as a high-affinity steroid-transport protein rather than as a classical proteinase inhibitor. This recombinant form is expressed in HEK293 mammalian cells, which supports the N-linked glycosylation patterns characteristic of the native secreted protein. Mammalian-cell expression is particularly relevant for CBG because its carbohydrate moieties influence both steroid-binding affinity and plasma half-life; insect- or bacterial-derived preparations typically lack these modifications and may not faithfully reproduce the native binding kinetics observed in physiological studies. Researchers use this recombinant in several experimental contexts. In steroid-binding assays, it serves as a defined, quantified protein standard to determine association constants for cortisol, corticosterone, and progesterone under controlled conditions. In ELISA-based workflows, it provides a reliable calibration standard or positive-control antigen for quantifying CBG in plasma, serum, or cell-conditioned media. For proteomics studies — including differential-expression and biomarker-discovery experiments — it can serve as a spiked reference to confirm detection of endogenous CBG bands. Researchers validating antibodies raised against SERPINA6 (including the matched Triple Point Biologics antibody, RP-SerpinA6) can use this recombinant as a confirmed-positive Western blot or ELISA control, removing ambiguity about band identity or signal specificity.

Background

Corticosteroid-binding globulin (CBG / Serpin A-6) is the dominant transport protein for circulating glucocorticoids and progestins in blood. By binding cortisol with high affinity, CBG effectively buffers the free hormone fraction available to tissues; because only free cortisol is thought to enter cells and activate glucocorticoid receptors, the concentration and binding capacity of CBG are determinants of glucocorticoid bioavailability. CBG is produced primarily by the liver, and its plasma levels fluctuate with physiological state — declining during acute inflammation, rising during pregnancy, and varying with estrogen exposure, a body of regulation reviewed in depth by Le Rouzic P (Front Endocrinol, 2025; PMID 41180195). The same comprehensive review covers the structural basis of CBG's steroid-binding serpin fold and documents genetic variants linked to CBG deficiency states that have been characterised in human cohorts as research subjects. Because CBG is a secreted glycoprotein produced at high levels by the liver, it is routinely detected in plasma proteomics datasets. Two recent studies illustrate the breadth of contexts in which SERPINA6 appears as a differentially expressed protein. Fatima S et al. (Steroids, 2026; PMID 42034305) used ELISA-based validation to confirm differential expression of SERPINA6 alongside other serpins in women with polycystic ovary syndrome (PCOS), demonstrating how a well-characterised recombinant standard is essential for accurate ELISA calibration in this type of proteomic-validation workflow. Separately, Wu L et al. (Int J Radiat Oncol Biol Phys, 2026; PMID 42176864) identified CBG as part of a longitudinal plasma proteome signature characterised in lung cancer patients undergoing radiation therapy, underscoring CBG's relevance as a detectable plasma protein in oncology research contexts. Zhang G et al. (Tissue Cell, 2026; PMID 42250534) identified CBG in comparative proteomic analyses of Achilles tendon tissue, highlighting its appearance in musculoskeletal disease proteomics datasets. Together, these publications reflect the protein's broad utility as a research target across endocrinology, reproductive biology, oncology, and connective tissue research. In addition to its role in steroid transport, CBG undergoes a conformational change upon cleavage of its reactive-centre loop by neutrophil elastase at sites of inflammation, releasing cortisol locally — a mechanism that makes CBG relevant to studies of the acute-phase response and local glucocorticoid signalling. Factors governing transcortin production and function in plasma, including hormonal and nutritional regulators, are characterised in Chevais A et al. (Probl Endokrinol, 2025; PMID 40734295). This recombinant reagent supports in-vitro mechanistic studies in all of these research areas.

Applications

  • ELISA calibration standard for quantifying endogenous CBG in plasma or serum samples
  • Steroid-binding kinetics assay: determination of association/dissociation constants for cortisol, corticosterone, or progesterone
  • Antibody validation positive control for Western blot and ELISA (pairs with matched Triple Point Biologics antibody RP-SerpinA6)
  • Proteomic spike-in reference to confirm SERPINA6 detection in differential-expression datasets
  • Competitive binding assay to assess displacement of cortisol by synthetic glucocorticoids or progesterone analogues
  • Reactive-centre loop cleavage assay: substrate for neutrophil elastase to study conformational change and steroid-release mechanism
  • Immunoprecipitation input control or bait protein for identifying CBG-binding partners in plasma or cell-conditioned media

References

  1. Zhang G et al. Comparative proteomic analysis reveals the pathological mechanisms of overuse achilles tendinopathy and the therapeutic mechanisms of ESWT and PRP. Tissue Cell. 2026. doi:10.1016/j.tice.2026.103674. PMID: 42250534.
  2. Wu L et al. Longitudinal Plasma Proteomics Reveals an Immuno-thrombotic Signature That Predicts Radiation Pneumonitis in Lung Cancer. Int J Radiat Oncol Biol Phys. 2026. doi:10.1016/j.ijrobp.2026.05.018. PMID: 42176864.
  3. Fatima S et al. ELISA-based validation of differentially expressed Fibrinogen, S100A9, SERPINA3 and SERPINA6 proteins in Polycystic Ovary Syndrome (PCOS). Steroids. 2026. doi:10.1016/j.steroids.2026.109791. PMID: 42034305.
  4. Le Rouzic P. Binding for life: corticosteroid binding globulin from vertebrate physiology to human diseases. Front Endocrinol (Lausanne). 2025. doi:10.3389/fendo.2025.1647096. PMID: 41180195.
  5. Chevais A et al. [Factors and conditions affecting transcortin production and function in blood plasma]. Probl Endokrinol (Mosk). 2025. doi:10.14341/probl13483. PMID: 40734295.

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; blood plasma

Frequently Asked Questions

What is the expected molecular weight of recombinant Serpin A-6 on SDS-PAGE and Western blot?

The mature human Serpin A-6 (CBG/Transcortin) protein spans 405 amino acids, giving a predicted unglycosylated MW of ~44 kDa. Because this recombinant is expressed in HEK293 cells, N-linked glycosylation adds substantial mass — expect a diffuse band running at approximately 52–58 kDa on reducing SDS-PAGE, consistent with the native plasma-derived protein. The smearing is characteristic of heterogeneous glycosylation and is not an indicator of degradation. Bacterially expressed or deglycosylated preparations will collapse toward ~44 kDa.

Does recombinant Serpin A-6 include the signal peptide, or is it the mature secreted form?

This preparation represents the mature secreted form of Serpin A-6 (UniProt P08185), with the 22-residue N-terminal signal peptide removed post-translationally during HEK293 secretory processing. The expressed sequence covers residues 23–427 (inclusive of the pro-region), matching the predominant circulating isoform. No additional propeptide cleavage tags have been introduced, so the N-terminus is authentic to native CBG. If your assay requires a specific terminal epitope, confirm antibody epitope coverage against the mature sequence before use.

Does neutrophil elastase cleave Serpin A-6 / CBG and release cortisol — can I replicate that with this recombinant?

Yes. Serpin A-6 contains a reactive center loop (RCL) that is cleaved by neutrophil elastase (HNE) between Thr345 and Leu346, inducing a conformational change that reduces steroid-binding affinity roughly 10-fold. To replicate this in vitro, incubate Serpin A-6 with HNE at a molar ratio of 1:50–1:200 (HNE:CBG) in 50 mM Tris-HCl pH 7.5, 150 mM NaCl at 37°C for 30–60 minutes. RCL-cleaved CBG runs at ~40 kDa on non-reducing SDS-PAGE due to the conformational shift. Cortisol displacement can be confirmed by competitive binding or equilibrium dialysis.

What buffer conditions are recommended for Serpin A-6 steroid-binding affinity assays?

Serpin A-6 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol, which is compatible with most equilibrium dialysis and fluorescence displacement assays without buffer exchange. For competitive binding experiments using tritiated cortisol or dexamethasone, dilute into PBS pH 7.4 containing 0.1% BSA to minimize non-specific adsorption to assay plates. Avoid phosphate concentrations >50 mM, which can slightly reduce binding affinity at physiological temperature (37°C). Reported Kd for cortisol binding to native human CBG is ~30–35 nM at 37°C; expect comparable values with this HEK293-derived preparation.

What starting concentration should I use for Serpin A-6 in a cortisol competition binding assay?

For a standard competitive binding assay using radiolabeled cortisol, a Serpin A-6 concentration of 50–200 nM (approximately 2.5–10 µg/mL based on ~52 kDa glycosylated MW) is a practical starting range. This places you near the Kd (~30–35 nM) so competition curves have adequate dynamic range. Verify active protein concentration by a steroid-binding assay rather than relying solely on total protein measurement by BCA, since glycosylation contributes ~20–25% of measured mass but not to binding stoichiometry. Titrate in at least 8 points across a 3-log concentration range for IC50 determination.

Can I use recombinant Serpin A-6 as a Western blot positive control with the matched TPB antibody RP-SerpinA6?

Yes — this recombinant is the intended positive control for the matched rabbit polyclonal antibody RP-SerpinA6 (/anti-serpin-a6-rabbit-polyclonal-antibody), which was raised and validated in the same workflow. Load 20–50 ng of recombinant Serpin A-6 per lane on a 10% SDS-PAGE gel under reducing conditions; expect a primary band at 52–58 kDa. At RP-SerpinA6 dilutions of 1:1,000–1:3,000, signal is typically clean with low background. This pairing is particularly useful when validating antibody lot-to-lot consistency or confirming positive signal in novel cell/tissue lysates where endogenous CBG expression is uncertain.

How much recombinant Serpin A-6 should I load as a positive control lane alongside tissue or plasma lysates?

20–50 ng per lane is sufficient to produce a clearly detectable band with RP-SerpinA6 at 1:1,000–1:2,000 dilution, and this load falls well below the linear saturation range of most HRP-based detection systems. For plasma samples, endogenous CBG runs at 55–60 kDa due to plasma-specific glycoforms, so the recombinant band at 52–58 kDa will co-migrate closely but can be distinguished by lane position. If running hepatocyte or liver lysates where CBG is synthesized, the recombinant control confirms antibody sensitivity against the mature secreted form rather than intracellular intermediates.

How should I store and handle recombinant Serpin A-6 to preserve steroid-binding activity over time?

Store at -20°C in the supplied single-use aliquots (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol). Repeated freeze-thaw cycles progressively denature the RCL and reduce cortisol-binding capacity; even two additional cycles can measurably reduce Kd fidelity. Upon first thaw, centrifuge briefly at 10,000 × g to pellet any micro-aggregates before use. Working dilutions in PBS/0.1% BSA are stable at 4°C for up to 48 hours. Do not dilute into detergent-containing buffers (e.g., 0.1% Tween-20) if steroid-binding activity is the endpoint, as mild detergents can partially unfold the binding pocket.

Validation imagery coming soon

Western blot validation figures for REC-SerpinA6 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →